Indo Us Biotech Intrinsic Value

INDOUSFast Moving Consumer GoodsSmall CapNSE

Market cap ₹108 CrEPS ₹1.85

Current market price

₹73.96

+₹1.21 (+1.66%)

NSE · 9 Oct 2026

Closing price

Intrinsic Value Estimate

Based on DCF and peer comparison with Bear / Base / Bull scenarios.

Final Intrinsic Value

₹158.08

+113.74% vs market

Undervalued

vs Market Price

+113.74%

Undervalued

Valuation range₹133.65 – ₹189.96

Bear
₹133.65Base
₹158.08central estimateBull
₹189.96

Scenario range reflects DCF assumptions and peer-multiple distribution.

Indo Us Biotech Intrinsic Value Analysis

The latest available EOD closing price for Indo Us Biotech (INDOUS) is ₹74 per share. Understock's estimated intrinsic value is ₹158 per share. This estimate is 113.7% above that price; the page's comparison band labels the shares undervalued.

The stored DCF estimate is ₹288, and the peer-based estimate is ₹88. The displayed value combines them using the stored DCF weight of 35% and peer weight of 65%. Peer comparison uses 8 matched industry companies and contributing P/E, P/B, EV/EBITDA multiples.

For context, available company data reports ROCE of 17.2% and P/E of 10.8×. These metrics describe the business and are not separate intrinsic-value estimates.

How Understock Calculates Intrinsic Value

Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. For Indo Us Biotech, the displayed estimate uses both stored values and their respective weights. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.

Review this company's DCF valuation · Learn how DCF works · Use the DCF calculator · See Indo Us Biotech peer valuation · What intrinsic value means

FCF adjusted for working capital timing. Based on earnings conversion.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Indo Us Biotech Peer Comparison

How this company stacks up against sector peers on valuation and quality metrics.

Fast Moving Consumer Goods · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Indo Us Biotech INDOUS · you	₹108 Cr	10.8×	1.5×	6.0×	14.2%	11.9%	21.4%
Sector median	—	13.4×	1.5×	7.4×	12.4%	1.1%	17.2%
Gulshan Polyols Limited GULPOLY	₹1,085 Cr	11.1×	1.6×	5.0×	14.9%	4.6%	25.1%
HMA Agro Industries Limited HMAAGRO	₹1,050 Cr	6.7×	1.2×	5.1×	17.5%	2.4%	29.2%
Uttam Sugar Mills Limited UTTAMSUGAR	₹1,010 Cr	12.1×	1.5×	—	12.4%	0.0%	—
Dwarikesh Sugar Industries Limited DWARKESH	₹977 Cr	25.7×	1.0×	14.5×	3.7%	2.2%	-12.6%
IFB Agro Industries Ltd IFBAGRO	₹961 Cr	14.9×	1.7×	—	11.3%	0.0%	—
Vadilal Enterprises Ltd. VADILENT	₹894 Cr	65.5×	17.7×	—	27.0%	0.0%	—
REGAAL RESOURCES LIMITED REGAAL	₹889 Cr	14.8×	—	—	—	0.1%	—
Magadh Sugar & Energy Limited MAGADSUGAR	₹824 Cr	12.1×	0.9×	9.8×	7.2%	5.1%	9.3%

Peer comparison verdict

Indo trades at a discount to sector peers on P/E (10.8× vs median 13.4×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.

Business quality

Valuation

P/E ratio

10.8×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

14.2%

ROCE

17.2%

ROA

—

Growth

Revenue CAGR (3yr)

21.4%

EPS CAGR (3yr)

21.9%

Efficiency

Asset turnover

—

FCF yield

-13.9%

Dividend yield

—

Liquidity & Solvency

Debt / Equity

0.01×

Debt / EBITDA

—

Interest coverage

7.2×

Current ratio

3.05×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹110 Cr

Net profit

₹13 Cr

Operating margin

—

Net margin

11.9%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

-₹12.58 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

-₹14.99 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹95 L

Equity

₹93 Cr

Debt / Equity

0.01×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

68.3%

FII

0.0%

-0.2 pp QoQ

DII

0.0%

Retail

31.7%

Trend over time (%)

Quarterly data

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Change (YoY)
Promoter	70.2%	70.2%	70.2%	70.2%	70.2%	70.2%	70.2%	70.2%	70.2%	70.2%	68.3%	68.3%	-1.9 ppYoY
FII (Foreign)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.0%	+0.0 ppYoY
DII (Domestic)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0 ppYoY
Retail	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	31.5%	31.7%	+1.9 ppYoY

Signals from the trend

📉

PromoterDown 1.9pp — worth monitoring for further declines

➡️

FIIStable

➡️

DIIStable

Overall cautious — promoter selling warrant monitoring.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.